Effectiveness and cost-effectiveness of prognostic markers in prostate cancer
β Scribed by Calvert, N W; Morgan, A B; Catto, J W F; Hamdy, F C; Akehurst, R L; Mouncey, P; Paisley, S
- Book ID
- 109997412
- Publisher
- Nature Publishing Group
- Year
- 2003
- Tongue
- English
- Weight
- 104 KB
- Volume
- 88
- Category
- Article
- ISSN
- 0007-0920
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Women with a family history of breast cancer are at increased risk for developing this neoplasm. Starting surveillance more frequently at a younger age than the general population and the possibility of undergoing genetic testing are options for their medical management. We analyzed the
Estimates of cost-effectiveness for prostate carcinoma screening require a review of current data, modeling efforts, and perspectives on societal impact and costs. ## METHODS. Recent data from the cancer registry of the Michigan Department of Community Health was assessed for incidence trends in r
## Abstract ## BACKGROUND The Prostate Cancer Prevention Trial (PCPT) demonstrated that finasteride reduces the prevalence of prostate cancer by 24.8% (risk reduction) but questions remain regarding the costβeffectiveness of widespread utilization. The purpose of the current analysis was to evalua
## BACKGROUND. Because the mortality rate from lung cancer is increasing sharply in Japan, lung cancer screening is being performed actively to assure early diagnosis and early treatment. However, its effectiveness is not clear, because it is extremely difficult to diagnose early microcarcinoma of